Maryam Lustberg, Director of the Center for Breast Cancer at Yale University School of Medicine, shared on LinkedIn:
“We focus often on vaginal estrogen as an important option for genitourinary syndrome of menopause (GSM).
What about vaginal DHEA/prasterone?
Highlighting here an important older study by National Cancer Institute (NCI) cooperative group Alliance for Clinical Trials in Oncology.
The formulation with palm oil (Intrarosa) can feel more soothing than vaginal estrogen suppositories and is an option to discuss with patients with GSM.”
Title: Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance).
Authors: Debra L. Barton, Jeff A. Sloan, Lynne T Shuster, Paula Gill, James D. Bearden, David B Johnson, Philip J. Stella, Shelby A. Terstriep, Fauzia N. Rana, Daniel M. Anderson, Charles L. Loprinzi
Title: Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)
Authors: Debra L Barton, Lynne T Shuster, Travis Dockter, Pamela J Atherton, Jacqueline Thielen, Stephen N Birrell, Richa Sood, Patricia Griffin, Shelby A Terstriep, Bassam Mattar, Jacqueline M Lafky, Charles L Loprinzi
Other articles about genitourinary syndrome of menopause on OncoDaily.